Natera (NTRA) is back in focus after securing Class C certification under the European Union’s In Vitro Diagnostic Regulation for its Signatera cancer test, a regulatory milestone that is tied to long term EU market access.

The IVDR milestone lands during a strong run for Natera’s stock, with a 30 day share price return of 26.49% and a 90 day share price return of 46.01%. The 1 year total shareholder return of 72.53% and very large 3 year total shareholder return signal sustained momentum around its cancer testing platform.

If this cancer testing story has your attention, it could be a good moment to look at other potential healthcare AI opportunities using our curated 40 healthcare AI stocks

After such a rapid move in Natera, the trade-off is clear: pay up for the momentum, or wait and risk watching the stock run without you. How do today's fundamentals stack up against that choice?

Most Popular Narrative: 8.4% Overvalued

Natera’s most followed narrative pegs fair value at $260.05, modestly below the last close of $281.85, raising clear questions about what is built into the story.

Investment in new product launches (e.g., Fetal Focus NIPT, Signatera Genome, AI-based biomarkers) and a robust R&D pipeline positions Natera to capture growth from long-term trends in personalized medicine and early detection, underpinning future revenue expansion.

Want to see what is behind that premium tag on Natera? The narrative leans on strong revenue compounding, higher margins, and a punchy earnings profile that drives the fair value call.

Result: Fair Value of $260.05 (OVERVALUED)

However, Natera’s story could look very different if clinical trials or reimbursement decisions disappoint, or if rising R&D and commercial spending delays a clear path to profitability.

Another View: SWS DCF Points to a Very Different Natera Valuation

While the most popular Natera narrative flags the stock as 8.4% overvalued against a $260.05 fair value, the SWS DCF model points in the opposite direction, suggesting the shares trade about 49% below an estimated future cash flow value of $552.95.

Two models, two very different answers. Which one better matches how you think cash flows and risk will actually play out for this business?

Simply Wall St performs a discounted cash flow (DCF) on every stock in the world every day (check out Natera for example). We show the entire calculation in full. You can track the result in your watchlist or portfolio and be alerted when this changes, or use our stock screener to discover 44 high quality undervalued stocks. If you save a screener we even alert you when new companies match - so you never miss a potential opportunity.

Next Steps

Interested in how balanced the Natera story really is right now? Take a closer look at the full picture and consider the 2 key rewards and 1 important warning sign.

Looking for more investment ideas beyond Natera?

If Natera has sharpened your interest in what is possible, do not stop at one stock when a few smart filters could reshape your entire watchlist.

• Target quality at a discount by scanning for companies that score well on fundamentals yet trade at appealing prices using the 44 high quality undervalued stocks.
• Lock in reliability by focusing on companies with robust finances through the solid balance sheet and fundamentals stocks screener (47 results).
• Spot tomorrow's potential standouts before the crowd by running the screener containing 19 high quality undiscovered gems.

This article by Simply Wall St is general in nature. We provide commentary based on historical data and analyst forecasts only using an unbiased methodology and our articles are not intended to be financial advice. It does not constitute a recommendation to buy or sell any stock, and does not take account of your objectives, or your financial situation. We aim to bring you long-term focused analysis driven by fundamental data. Note that our analysis may not factor in the latest price-sensitive company announcements or qualitative material. Simply Wall St has no position in any stocks mentioned.